Lightnews — Scholar-powered news

Dr. Don S Dizon @drdonsdizon.bsky.social · Jun 2

For people with metastatic PDL1+ TRIPLE NEG BREAST CANCER, Sacituzumab+pembrolizumab (P) significantly increases PFI by ~3m vs chemo+P (a 35% improvement). Whether its meaningful depends on the person offered it and whether it will ultimately improve OS. #ASCENT meetings.asco.org/abstracts-pr... 8/8

Program Guide – ASCO Meeting Program Guide

meetings.asco.org

2

Dr. Don S Dizon @drdonsdizon.bsky.social · Jun 2

For people with advanced hormone receptor positive PIK3CA mutated BREAST CANCER, 1st line tx w/ inavolisib|palbociclib|fulvestrant (PF) increased OS over placebo + PF by 7 months- an almost 30% improvement. 30-month overall survival was also improved by 10%. meetings.asco.org/abstracts-pr... 7/8

Program Guide – ASCO Meeting Program Guide

meetings.asco.org

1 3

Dr. Don S Dizon @drdonsdizon.bsky.social · Jun 2

Its not a randomized trial, but the results are reassuring. #KCSGBR18-2 www.asco.org/abstracts-pr... 6b/8

Phase IB and II study of ribociclib with trastuzumab plus endocrine therapy in HR+/HER2+ advanced breast cancer patients: Korean Cancer Study Group BR 18-2 MINI trial. - ASCO

www.asco.org

1 2

Dr. Don S Dizon @drdonsdizon.bsky.social · Jun 2

For people with metastatic triple-positive BREAST CANCER (Hormone and HER2 positive), one trial of 77p reported that ribociclib, trastuzumab, and letrozole resulted in a 61% overall response rate and median progression-free interval of 30 months. 6a/8

Phase IB and II study of ribociclib with trastuzumab plus endocrine therapy in HR+/HER2+ advanced breast cancer patients: Korean Cancer Study Group BR 18-2 MINI trial. - ASCO

www.asco.org

1 1 5

Dr. Don S Dizon @drdonsdizon.bsky.social · Jun 2

Whether monitoring blood for ctDNA over time improves overall survival through earlier intervention has to be proven. But the best med will always be the one someone is willing to stay on. #SERENA6 meetings.asco.org/abstracts-pr... 5b/8

Program Guide – ASCO Meeting Program Guide

meetings.asco.org

1

Dr. Don S Dizon @drdonsdizon.bsky.social · Jun 2

In the absence of frank disease progression, for people with hormone-positive BREAST CANCER, the only reason to switch treatment from an aromatase inhibitor (AI) to a selective estrogen receptor degrader (SERD) is if toxicity is making it hard to take the AI. 5a/8

Program Guide – ASCO Meeting Program Guide

meetings.asco.org

1 3

Dr. Don S Dizon @drdonsdizon.bsky.social · Jun 2

Interestingly, the OS benefit was bigger than the Progression Free Interval which was improved by only one month. It also added no additional toxicity to treatment. 4b/8 #ROSELLA ascopubs.org/doi/10.1200/...

ASCO Publications

ascopubs.org

1 1

Dr. Don S Dizon @drdonsdizon.bsky.social · Jun 2

For people with platinum-resistant recurrent OVARIAN CANCER, a novel drug that targets the glucocorticoid receptor, called Relacorilant, in combination with nAb-paclitaxel improved overall survival (OS) by 5 months over nAb-paclitaxel alone. 4a/8 #ROSELLA

1 2

Dr. Don S Dizon @drdonsdizon.bsky.social · Jun 2

For people with OVARIAN CANCER, surgery should be done if their gyn onc feels they can have all tumor resected rather than undergoing medical therapy (neo adjuvant chemo) first. That’s been the standard everywhere I’ve worked and the #TRUST trial affirms this. meetings.asco.org/abstracts-pr... 3/8

Program Guide – ASCO Meeting Program Guide

meetings.asco.org

1 2

Dr. Don S Dizon @drdonsdizon.bsky.social · Jun 2

PFS (Progression Free Survival) needs to be renamed. People don’t experience “progression”. A cancer may progress at some interval, and that’s what it should be called: PFI. The only survival is whether one is alive or dead- OS (Overall Survival). We need to stop conflating them. 2/8

1 6

Dr. Don S Dizon @drdonsdizon.bsky.social · Jun 2

As I make my way home from #Chicago (finally!) here's what I come away with from #ASCO25
I had hoped to live blog from the meeting but time got the better of me! Here goes.... 1/8

1 4 8

Dr. Don S Dizon @drdonsdizon.bsky.social · Jun 1

Yes, so great to see you

1 1 1

Dr. Don S Dizon @drdonsdizon.bsky.social · May 31

Have fun at your #asco25 session. I will be watching remotely and rooting for you all the same.

1

Dr. Don S Dizon @drdonsdizon.bsky.social · May 30

I shared the ASCO stage with Dr Dawn Hershman when we were both awarded a career development award as we were starting our careers. Amazing to share the stage with her again as we are awarded once more at #ASCO25. Truly honored and excited to do so.

2 3 22

Dr. Don S Dizon @drdonsdizon.bsky.social · May 30

Blush

2

Dr. Don S Dizon @drdonsdizon.bsky.social · May 21

I'm officially Professor of Medicine at @tuftsmedschool.bsky.social
Yowza.

5 18

Dr. Don S Dizon @drdonsdizon.bsky.social · May 18

I'm proud to be a part of this international community seeking to improve both access and outcomes for people with breast cancer worldwide.

1

Dr. Don S Dizon @drdonsdizon.bsky.social · May 18

a great 4d in #Munich with @myesmo.bsky.social. Spoke on the importance of sex after cancer & chaired a session on Breast Cancer in Young Women. With @tanjaspanic.bsky.social from #Slovenia my pal Matteo Lambertini from #Italy, Prof Inez Vaz-Luis from #France, and Antigoni Kretsi from #Greece

2 2 9

Reposted by Dr. Don S Dizon

Megan Ranney MD MPH @meganranney.bsky.social · May 16

… and Molly is not alone. More than $2.6B of ongoing research has been canceled (with much more this week, at Harvard).

With each cancellation: We are losing so much knowledge. Losing the next generation of scientists. Losing our ability to protect our health, both now & for the future. 🧪🩺😷

Molly Franke @mollyfranke.bsky.social · May 15

All 4 of my NIH research grants are terminated. These were grants on MDR-TB treatment & strategies for supporting adolescents living w/ HIV. This is a massive waste of resources. I am heartbroken for my Harvard team, my partners in Peru, the next generation of scientists & our country. Shame.

2 79 220

Dr. Don S Dizon @drdonsdizon.bsky.social · May 9

Leaving for #Munich next week for #ESMOBreast25 Excited to catch up w/ colleagues, especially as I renew my practice in breast oncology @tuftsmedicine.bsky.social If you are interested in joining me, we have a pretty great opportunity! Check it out and LMK.
careers.tuftsmedicine.org/us/en/job/R1...

Breast Oncologist in Boston, Massachusetts, 02111-1552 | Physicians and Advanced Practice Clinicians at Tufts Medicine

Apply for Breast Oncologist job with Tufts Medicine in Boston, Massachusetts, 02111-1552. Physicians and Advanced Practice Clinicians at Tufts Medicine

careers.tuftsmedicine.org

1 5

Reposted by Dr. Don S Dizon

Binaytara @binaytara.bsky.social · Apr 26

The community engagement session led by @drdonsdizon.bsky.social at #SCHD25 demonstrated impactful outcomes. The work of Dr. Memnun Seven with cancer survivors, Dr. Andrew Sussman's CAB strategies, and Dr. Vida Henderson's media approaches show that authentic partnerships improve results.

2 5

Dr. Don S Dizon @drdonsdizon.bsky.social · Apr 21

I'm not practicing much but I am who I am because of my very Catholic parents who taught me right from wrong and to care for everybody. I admired Pope Francis. He will be missed in this very turbulent world.

IrishStar.com @irishstar.com · Apr 21

The Catholic world is in mourning after the passing of Pope Francis, sparking questions about who will take on the role as the head of the Vatican.

Who will be the next Head of the Catholic Church after Pope Francis' death?

www.irishstar.com

1 1 7

Dr. Don S Dizon @drdonsdizon.bsky.social · Apr 14

Huge congratulations!!!!

1 2

Reposted by Dr. Don S Dizon

Nathan Pennell MD, PhD, FASCO @n8pennell.bsky.social · Apr 14

So excited to kick off the first episode of our new podcast: ASCO Education: By the Book with good friend and former #EdBook editor @drdonsdizon.bsky.social!

@ascocancer.bsky.social ascoeducation.libsyn.com/the-evolutio...

ASCO Education: The Evolution of the ASCO Educational Book and the Issues Shaping the Future of Oncology

On the inaugural episode of ASCO Education: By the Book, Dr. Nathan Pennell and Dr. Don Dizon share reflections on the evolution of the ASCO Educational Book, its global reach, and the role of its new...

ascoeducation.libsyn.com

4 9

Dr. Don S Dizon @drdonsdizon.bsky.social · Apr 10

Sexuality is so innately human we need to be able to talk about it for people with cancer. Join me, Linda Bosserman, and @drannekatz.bsky.social to do just that.
And thanks to @cancercaremascc.bsky.social for offering this!

MASCC @cancercaremascc.bsky.social · Apr 3

Join us for a two-day interactive course on the fundamentals of sexual health after a cancer diagnosis. The course will run from June 25 - 26, with co-chairs @lindabosserman.bsky.social and @drannekatz.bsky.social and additional faculty member @drdonsdizon.bsky.social

mascc.org/annualmeetin...

1 4